BioByte 074: Why Mars is tough for life, an autoantibody signature for MS, selective compartmentalization for proteins, AI-designed CRISPR, RNAi-based drug design
BioByte 071: Unanswered questions, paused base-editing therapy, challenges with ASOs, GPT-4 for cell type annotation, the scientific journey behind Ozempic
BioByte 069: AI learns the meaning of life, the dysfunctome, a $400M launch for inflammatory drugs, Nvidia's 'woodstock' and engineering crops to save the planet
BioByte 068: Cell therapy for solid tumors, using a monoclonal for allergy, improving AlphaFold2 performance, using ML to understand small RNA secretion, Insilico's development of a TNIK inhibitor
BioByte 067: DNA foundation models, neural multi-task learning for drug design, non-invasive methods for brain amyloid clearance, clinical trial architectures for precision medicine
BioByte 066: CAR-T for MS, will AI replace animal testing, diagnosis of ultra-rare monogenic disorders, BigRNA: a foundation model for RNA biology, Matter Neuro raises $26M to “cure unhappiness"
BioByte 065: RNA-editing therapies pick up steam, experts speak on protein design, decoding the autoantibody reactome, links between menopause and healthy aging, and more
BioByte 063: How to develop a blockbuster, unravelling the biology of autoimmunity, partnering with pharma and a new model for intrinsically disordered proteins.